Opendata, web and dolomites

Facer SIGNED

The First Cell Culture Platform that Enables Affordable Cell Therapies at a Large Scale

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Facer project word cloud

Explore the words cloud of the Facer project. It provides you a very rough idea of what is the project "Facer" about.

injected    describe    performances    regulatory    gain    36    hinders    tissue    infrastructure    human    quality    specialised    asks    approved    life    ebitda    globally    platform    approval    trl    quantity    ce    therapy    medical    principles    intervention    iterative    patients    therapies    market    2024    tackle    curing    quantities    successfully    autonomous    validation    manufacture    expand    blood    affordable    afford    nowadays    innovation    small    treatments    course    marking    investments    customer    billions    culture    biopsy    turnover    first    diabetes    sale    deemed    centres    distributor    diseases    initially    conclude    500    starting    cash    cells    cell    few    possibly    lower    suffer    local    competitor    patented    external    modified    cancer    launching    culturing    perform    treating    millions    2018    shown    commercially    finalise    once    surpass    scalable    august    thanks    million    barriers    facer    device    superior    incurable    overcome   

Project "Facer" data sheet

The following table provides information about the project.

Coordinator
AGLARIS LIMITED 

Organization address
address: STEVENAGE BIOSCIENCE CATALYST, F30, GUNNELS WOOD R
city: STEVENAGE
postcode: SG1 2FX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙051˙000 €
 EC max contribution 1˙435˙700 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AGLARIS LIMITED UK (STEVENAGE) coordinator 1˙435˙700.00

Map

 Project objective

Cell therapy has shown promising results for treating and curing a large range of diseases, from cancer to diabetes. The principles of cell therapy are easy to describe: cells (possibly modified) are injected into patients. Cell therapy is now a reality in Europe: in August 2018 the first two treatments for patients with blood cancer were approved; more of them are about to successfully conclude the approval path. What hinders the large-scale uptake of cell therapy is its costs: culturing enough cells of high quality requires specialised personnel and infrastructure, which only a few centres can afford. The market asks for a scalable cell culture platform that can produce large quantities of high quality cells at much lower costs than done nowadays. To address this need, we have developed the Facer – the first fully-autonomous cell culture platform. The Facer can manufacture billions of high-quality cells starting from the small quantity (about 500,000 cells) of a tissue biopsy without the need of human intervention, thanks to a unique patented iterative process. Our product is at TRL 7; its performances, in terms of quality and costs, are superior to any competitor commercially available. We have developed the Facer over the course of 5 years thanks to cash investments of over €3 million. In the Phase 2 project we will finalise the product, perform a validation with external partners, gain the CE marking (our product is not a medical device), and find a distributor and a launching customer. We will initially tackle the European market to then expand globally once that the local regulatory barriers are overcome. In 2024, after 5 years from the first sale, our turnover will surpass the €60 million and our EBITDA will be over €36 million. Our innovation can enable affordable cell therapies at a large scale and change the life of millions of patients who suffer from diseases that have been deemed 'incurable' so far.

 Publications

year authors and title journal last update
List of publications.
2019 Mireia Ruiz
Development of an autonomous platform for CAR T-cell manufacturing
published pages: , ISSN: , DOI:
National Instrument case – Real world applications 2020-04-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FACER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FACER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More